Mesoblast (ASX:MSB) acquired an exclusive license to a patented chimeric antigen receptor technology platform to boost the effectiveness of its products, according to a Wednesday filing with the Australian bourse.
The company obtained the rights to the intellectual property developed at Mayo Clinic through the acquisition of a startup mainly formed to advance the technology, the filing said.
Shares rose nearly 7% in morning trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments